China Botanic Pharmaceutical Inc. reported unaudited consolidated earnings results for the second quarter and six months ended April 30, 2012. For the quarter, the company reported sales, net of $23,022,385 compared to $18,873,689 a year ago. Revenue growth during the quarter was mainly due to increasing market acceptance of the company's Siberian Ginseng Series products, Compound Honeysuckle Granules and increasing revenue contribution from its new Ginseng and Venison Extract product. Income from operations was $9,204,265 compared to $8,028,774 a year ago. Income before income tax expenses was $9,237,084 compared to $8,051,727 a year ago. Net income was $7,850,121 or $0.21 basic and diluted per share compared to $7,081,056 or $0.19 basic and diluted per share a year ago. For the six months period, the company reported sales, net of $51,162,476 compared to $41,498,749 a year ago. Income from operations was $23,654,915 compared to $19,676,312 a year ago. Income before income tax expenses was $23,719,841 compared to $19,723,454 a year ago. Net income was $20,157,353 or $0.54 basic and diluted per share compared to $18,029,351 or $0.48 basic and diluted per share a year ago. Net cash provided by operating activities was $14,193,182 compared to $16,100,490 a year ago. For fiscal year 2012, the company reaffirms its guidance of revenues of between $91.6 million and $93.1 million, representing an increase of 26% to 28% over fiscal year 2011 revenue of $72.7 million. Revenue growth is expected to be driven largely by sales volume increases from the existing product portfolio. The company expects net income to be in the range of $32.7 million to $33.2 million, representing an increase of between 26% and 28% over fiscal year 2011 net income of $25.9 million.